arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

NRX Pharmaceuticals, Inc.

NRXP

$3.57 ▲ +0.49 (+15.91%) at close

9 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

NRX Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $76.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 80.4% ↗

FCF / Share $-0.66 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.23M

— —

Net Income Profit after all expenses

$-28.62M

↓ -13.9% —

FCF / Share Free cash flow per share

$-0.66

↑ +34.0% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns ↑

100

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	43.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	40.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-563.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	97.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-31.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-13.9% Weak ↓ Weak Declining Year-over-year change in net income	16.7% Good ↑ Good Improving Year-over-year change in net income	24.2% Good ↑ Good Improving Year-over-year change in net income	57.3% Excellent ↓ Excellent Declining Year-over-year change in net income	-79.7% Weak Weak Year-over-year change in net income	N/M	517.9% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	34.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	65.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-372.9% Weak ↑ Weak Improving Year-over-year change in free cash flow	92.5% Excellent Excellent Year-over-year change in free cash flow	-1115.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	—	—	—	17.1% Good Good Actual taxes paid relative to pre-tax income Optimal: 15-25%	19.8% Good Good Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.49x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.42x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.04x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-1.94x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-7.16x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	80.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	62.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	187.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-195.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-439.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	92.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-11.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-16.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-125.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-506.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-380.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-171.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-353.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-1747.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-2.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-1.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	179.6% Excellent → Excellent Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1097%)	108.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+621%)	257.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1613%)	—	—	118.3% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+689%)	8.2% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-46%)	1.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-91%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Debt to Equity (x)	—	—	—	1.42x Caution Caution Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+137%)	—	—	—	—	—
Interest Coverage (x)	—	-49.47x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-31.45x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	—	-6433.11x Weak Weak Operating income divided by interest expense Optimal: > 5x	-917.62x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-7.80M	$-1.44M	$-4.59M	$-9.53M	$-27.61M	—	—	—	—
Debt / EBITDA (x)	—	—	—	-0.24x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$0.06	$0.00	$0.00	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.34	$-2.36	$-3.98	$-0.60	$-19.80	$-15.10	—	—	—
Free Cash Flow per Share (USD)	$-0.66	$-1.00	$-2.86	$-0.60	$-8.04	$-0.66	—	—	—
Book Value per Share (USD)	$-0.50	$-1.59	$-1.40	$0.11	$3.54	$-10.19	$21.69	$18.35	$0.00
Tangible Book Value per Share (USD)	$-0.59	$-1.59	$-1.40	$0.11	$3.54	$-10.19	$21.69	$18.35	$0.00
Basic Weighted Avg Shares (shares)	21.40M	10.64M	7.58M	65.77M	4.69M	3.43M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$-19.69M	$-18.56M	$-12.16M	$10.21M	$20.79M	$-43.23M	$-552.95K	$-537.22K	$443.20K
LT Debt (USD)	—	—	—	$10.53M	—	—	—	—	—
Total Equity (USD)	$-15.94M	$-23.22M	$-11.73M	$7.41M	$20.81M	$-43.77M	$5.00M	$5.00M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$1.23M	$0.00	$0.00	—	—	—	—	—	—
Depreciation Expense (USD)	$10.00K	$10.00K	$5.00K	$4.00K	$2.00K	$2.00K	—	—	—
Net Income, GAAP (USD)	$-28.62M	$-25.13M	$-30.15M	$-39.75M	$-93.06M	$-51.78M	$408.43K	$66.10K	—
Operating Cash Flow (USD)	$-14.11M	$-10.64M	$-21.66M	$-39.76M	$-37.70M	$-2.27M	$-792.73K	$-473.19K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters

NRX Pharmaceuticals, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NRXP with peers